PBYI - Puma Bio's neratinib improves overall survival in early stage HER2+ breast cancer patients

Puma Biotechnology ([[PBYI]] +3.2%) presents results from the Phase III ExteNET trial assessing the impact of neratinib treatment duration on overall survival ((OS)) in patients with early stage HER2-positive breast cancer at the virtual 2021 ASCO Annual Meeting. Among patients who completed ? 11 months of neratinib therapy, overall survival ((OS)) (median follow-up of 8.0 years) was improved vs. placebo in each of the 3 groups.In the intention-to-treat ((ITT)) population, 872 of 1420 patients (61.4%) in the neratinib arm completed ? 11 months of treatment; OS rates were 92.2% vs 90.2% in the neratinib vs placebo arms, respectively, corresponding to a 2.0% improvement (HR 0.78; 95% confidence interval ((CI)) 0.58-1.04).In the HR+/?1 year patient population, 402 of 670 patients (60%) in the neratinib arm completed ? 11 months of treatment; OS rates were 95.2% in the neratinib vs 89.4% in placebo arms, corresponding to a 5.8% improvement (HR 0.49; 95% CI

For further details see:

Puma Bio's neratinib improves overall survival in early stage HER2+ breast cancer patients